At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4,918 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
In Brief
An observational study for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 4,918 participants.
Detailed Summary
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
Countries--
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
Primary CompletionFeb 2008
First PostedFeb 2008
TodayJul 2026
First PostedFeb 22, 2008
Enrollment StartMay 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago